Viatris Inc. (VTRS)
割安ファンダメンタル
49
株価
$17.64
時価総額
$20.35B
パート1 · 企業の価値
概要
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$14.69B
直近12か月（2026/6/30まで）
純利益
$-411M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$1.94B
自己資本合計
$14.71B
負債合計
$22.48B
流動比率
1.58
利払い倍率
0.18
負債/EBITDA
100.79
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$29.66
現在株価
$17.64
安全マージン
+40.5%
適正価値レンジ
$19.28 - $40.04
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-23.9%
P/B レシオ
1.43
P/FCF
10.41
粗利益率
34.9%
ROIC
-0.2%
収益性レーダー
価値創造（経済的モート）
ROIC
-0.2%
WACC
6.8%
ROIC − WACC
-7.0 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（12）
- Gross Margin 34.9%
- P/FCF 10.41
- P/B Ratio 1.43
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- DCF valuation (Undervalued)
- Analyst Consensus 65% Buy
- Earnings Surprise avg 9.6%
- Share Dilution -2.1%
- Net Margin Trend -2.8% vs -24.7%
不合格（11）
- EPS shows upward trend
- Price CAGR -7.70%
- ROIC -0.2%
- Operating Margin -0.6%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -2.8%
- Revenue Growth 5Y 3.7%
- Piotroski F-Score 4/9
データなし（4）
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
低品質：会計処理を調査してください
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Scott Andrew Smith Ph.D. | CEO & Director | 63 |
| Mr. Andrew Enrietti | Chief Administrative & Transformation Officer | 40 |
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer | 60 |
| Mr. Paul B. Campbell | Interim CFO, Chief Accounting Officer & Corporate Controller | 58 |
| Mr. Ramkumar V. Rayapureddy | Chief Information Officer | - |
| Mr. William Szablewski C.F.A. | Head of Investor Relations & Capital Markets | - |
| Mr. Matthew Joseph Maletta | Chief Legal Officer | 53 |
| Ms. Lara Ramsburg | Chief People & Corporate Affairs Officer | - |
| Mr. Philippe Martin | Chief R&D Officer | 49 |
| Mr. Peter McCormick | Chief Supply Officer | - |
監査リスク
5
取締役会リスク
1
報酬リスク
5
株主権利リスク
7
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for VTRS, sourced from Markets Gazette.